Further studies should elucidate if the ability of HLA-B*44 to efficiently present an encephalitogenic MBP peptide may affect MS’s course, probably due to the exhaustive thymic negative selection of myelin-reactive—or induction of regulatory MBP-specific—CD8+ T cells [38,39]. This evidence concerns the gene MBP and myeloid sarcoma.